Table 3.

Prevalence of the TMPRSS2:ERG gene fusion in men with prostate cancer from studies in the meta-analysis

Overall fusion analysisFusion mechanism analysis
CharacteristicSample sizePrevalence fusion positiveSample sizePrevalence fusion-by-deletiona
Overall10,77946.9%1,39063.7%
Assayb
 FISH3,14642.4%1,00862.6%
 RT-PCR1,31152.2%NANA
 IHC4,76351.8%NANA
Cohort continentb,c
 Asia83723.4%6761.2%
 Europe4,92653.6%38063.9%
 North America3,21747.6%53063.2%
Tissue assayed
 Biopsy61143.0%19060.0%
 Lymph node7159.2%0NA
 RP specimen9,22048.6%1,03563.1%
 TURP specimen80329.8%16571.5%
 Urine7436.5%0NA

Abbreviations: RP, radical prostatectomy.

  • aAmong those for whom fusion mechanism was determined.

  • bIn radical prostatectomy specimens only.

  • cExcludes cohorts with patients from multiple regions or areas outside those listed.